Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid leukemia (AML).
The names of the study drugs involved in this research study are:
* Venetoclax (a type of BCL-2 inhibitor)
* Azacitidine (a type of Demethylating Agent)
* Eganelisib (a type of PI3K-gamma inhibitor)